Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. is one of the world's largest independent biotechnology companies, developing biologic therapies that address serious illnesses across oncology, cardiovascular disease, inflammation, and other therapeutic areas. The company's news flow reflects its position as a major pharmaceutical innovator, with developments spanning regulatory approvals, clinical trial results, financial performance, and strategic initiatives.
Following Amgen's news provides insight into the biotechnology sector's evolution and the regulatory pathway for bringing complex biologic therapies to market. The company regularly announces FDA decisions on new therapies and expanded indications for existing products, offering real-time visibility into which treatments are gaining regulatory approval and market access. Clinical trial data releases reveal the company's research progress across its development pipeline, while earnings reports detail financial performance across geographic markets and product portfolios.
Amgen's announcements frequently include updates on cardiovascular therapies targeting cholesterol management, oncology supportive care products, and treatments for inflammatory conditions and bone health disorders. The company also announces manufacturing expansions that signal investment in biomanufacturing capacity and strategic moves including acquisitions, partnerships, and licensing agreements that shape its therapeutic portfolio. Investor presentations and analyst conferences provide management's perspective on business priorities and market dynamics affecting the broader biologics sector.
This news feed aggregates material disclosures, regulatory milestones, and corporate developments specific to Amgen, providing a centralized resource for tracking one of biotechnology's pioneering companies as it navigates an increasingly competitive landscape shaped by biosimilar competition, pricing pressures, and evolving therapeutic approaches.
Amgen will release its first quarter financial results on April 27, 2023, post market closure. The announcement will be followed by a conference call at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. Participants can access a live audio broadcast of the call, which will be available for replay for at least 90 days. Amgen, a leading biotechnology firm with a rich pipeline of medicines, was recognized in 2022 by Forbes as one of the "World's Best Employers" and by Barron's as one of "America's 100 Most Sustainable Companies." The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 index.
Amgen announced that the U.S. Court of Appeals for the Federal Circuit upheld the validity of its patent for Otezla (apremilast), which is set to expire in February 2028. This ruling affirms a previous injunction preventing Sandoz and Zydus Pharmaceuticals from producing generic versions of Otezla during this period. The court validated U.S. Patent No. 7,427,638 and U.S. Patent No. 7,893,101 related to Otezla, while ruling against Amgen on U.S. Patent No. 10,092,541. Otezla is approved for treating plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's Disease.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
